RD125 / IASO BIO 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RD125 / IASO BIO
NCT04767308: Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Not yet recruiting
1
18
NA
CT125A cells, Cyclophosphamide, fludarabine
Huazhong University of Science and Technology, Shanghai IASO Biotechnology Co., Ltd
CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Peripheral T-cell Lymphomas (PTCL)
09/23
12/23

Download Options